The FLAMINGO-01 DSMB met twice in 2025, most recently in December 2025, and recommended to continue the study as is without modification. The Steering Committee also met at SABCS 2025 and discussed ...
Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01 ...
Poherdy can be dispensed as a substitute for Perjeta without requiring a prescription change from a health care provider.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback